Company: MDCXW
Filing Date: 2025-05-30
Form Type: 424B4
Source: 0001062993-25-010548
Chunk: 0

Company: Medicus Pharma Ltd.
Filing Date: 2025-05-30
Form: 424B4
Chunk 0
---
Filed Pursuant to Rule 424(b)(4)

Registration No. 333-287599

Prospectus

<div align='center'>2,260,000 Units
Consisting of an Aggregate of
2,260,000 Common Shares
and
2,260,000 Warrants to Purchase One Common Share

2,260,000 Common Shares Issuable upon the Exercise of the Warrants

Medicus Pharma Ltd.</div>

We are offering on a “best efforts” basis 2,260,000 units (each, a "Unit"), each Unit consisting of one common share of Medicus Pharma Ltd. (the "Company", "we", "us"), no par value, and one warrant to purchase one common share (each, a "warrant") at a public offering price of $3.10 per Unit, for an aggregate offering of 2,260,000 common shares and 2,260,000 warrants and gross proceeds of $7.0 million. Each warrant is immediately exercisable for one of our common shares at an exercise price of $3.10 per share (or 100% of the price of each Unit sold in the offering) and will expire five years from the date of issuance. The Units will not be certificated and the common shares and warrants comprising the Units are immediately separable and will be issued separately in this offering. Pursuant to this prospectus, we are also offering the 2,260,000 common shares issuable from time to time upon the exercise of the warrants offered hereby.

Our common shares and public warrants, with an exercise price of $4.64 and expiration date of November 15, 2029 (the “Public Warrants”) are listed on Nasdaq, under the symbols "MDCX" and "MDCXW," respectively. The warrants offered hereby will not trade on any U.S. securities exchange and we will not apply for listing on any U.S. securities exchange. Therefore, without an active trading market for the warrants, the liquidity of such warrants will be limited.

The closing prices of our common shares and Public Warrants on Nasdaq on May 29, 2025 were $3.64 and $1.00, respectively.

The securities will be offered at a fixed price and are expected to be issued in a single closing. We expect this offering to be completed not later than one business day following the commencement of sales in this offering (after the effective date of the registration statement of which this prospect